我怎么感觉最后一句话的逻辑不对？

Ticagrelor, a reversible and direct-acting oral antagonist of the adenosine diphosphate receptor P2Y12, is an active drug and provides more consistent P2Y12 inhibition than pro-drug clopidogrel. Ticagrelor is associated with dose-related episodes of dyspnea, via an unknown mechanism, and ventricular pauses. As many as 14% of patients initiated on ticagrelor experience dose-dependent dyspnea which is described as “sudden and unexpected air hunger” or unsatisfied inspiration. Ticagrelor-related dyspnea typically begins within 1 week, but up to one-third may present within 24 hours. It is usually a diagnosis of exclusion after ruling out any other cardiopulmonary cause. This is especially challenging when presentation is soon after acute coronary syndrome. The symptoms resolve with cessation of ticagrelor therapy. Careful attention must be paid at the timing of cessation of ticagrelor and initiation of an alternative P2Y12 inhibitor such as clopidogrel or prasugrel.

替格瑞洛是一种腺苷二磷酸受体P2Y12的可逆性和直接作用口服拮抗剂，是一种活性药物，与前体药物氯吡格雷相比，可提供更一致的P2Y12抑制。替格瑞洛与剂量相关的呼吸困难发作（通过未知机制）和心室停搏相关。多达14%开始替格瑞洛治疗的患者出现剂量依赖性呼吸困难，被描述为“突然和非预期的空气饥饿”或吸气不满意。替格瑞洛相关呼吸困难通常在1周内开始，但高达1/3可能在24小时内出现。通常是排除任何其他心肺原因后的排除诊断。当急性冠状动脉综合征后不久就诊时，这尤其困难。停止替格瑞洛治疗后，症状消退。在停用替格瑞洛和开始使用替代P2Y12抑制剂（如氯吡格雷或普拉格雷）时，必须多加观察。

我怎么感觉最后一句话的逻辑不对，应该是停用如氯吡格雷或普拉格雷时，开始使用替格瑞洛时，必须多加观察，逻辑才是正确的